Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Pfizer: Sun Setting On Blockbuster Model

This article was originally published in The Pink Sheet Daily

Executive Summary

Industry execs chart move away from “bull’s eye” toward risk sharing.

You may also be interested in...

Personalized Medicine Not A Threat To Blockbuster Model - Lilly President Lechleiter

Pharma has rarely pursued one-size-fits-all strategies, instead segmenting disease categories or patient groups, an effort personalized medicine can only render more relevant and meaningful, exec says.

Pfizer Unveils New San Francisco-Based Biotech Center, R&D Leaders

Firm names Global R&D-VP Martin Mackay to succeed LaMattina, taps former Merck exec to head clinical development.

Bristol And Pfizer Team Up To Develop Anticoagulant Apixaban In $1 Billion Deal

In a separate agreement, the firms will also collaborate on the development of Pfizer’s preclinical metabolic disorder compounds.

Related Content





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts